retatrutide ly3437943 triple agonist gip glp-1 glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% GLP-3 (R) - Triple GIP

[DOI] [PubMed] [Google Scholar] 215

Cortes :Writing review & editing, Investigation, Formal analysis, Conceptualization

its just that not as much is required before Im satiated

12 A study shows the reduced GABA concentrations in the SM1 brain region in children with TS, with these levels correlating to the convulsion severity

It is non-hormonal and naturally occurring in the body as well as many foods common to the diet

A systematic review and meta-analysis of 12 randomized controlled trials (RCTs) involving 11 459 overweight or obese adults without diabetes demonstrated that GLP-1 receptor agonists significantly reduced body weight, alongside notable improvements in glycemic control, lipid levels, and blood pressure